Navigation Links
Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
Date:10/16/2007

Up to One Quarter of Managed Care Organizations Fail to Cover Agents with Proven Benefit for Cancer Patients, According to a New Report from Decision

Resources

WALTHAM, Mass., Oct. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists want to see significant improvement in overall survival before adopting targeted polypharmacy in first-line settings. According to the new Physician & Payer Forum report entitled Premium-Priced Targeted Agents in Oncology: Clinician and Payer Attitudes to Polypharmacy, surveyed oncologists were asked what the minimum benefit is that would persuade them to add ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux to Genentech/Roche's Avastin and chemotherapy for first-line treatment of advanced non-small-cell lung cancer (NSCLC).

In this first-line treatment scenario, the largest group of oncologists (41 percent) would require a significant improvement in overall survival in order to add Erbitux to Avastin and chemotherapy. On average, oncologists require 24 percent improvement in median survival, which would represent close to three months' additional survival, a very difficult requirement to meet in advanced NSCLC. Only 37 percent of oncologists expect Erbitux/Avastin to increase median survival of NSCLC patients.

The report also finds that up to one quarter of managed care organizations (MCOs) fail to cover both agents where two similar targeted agents are available. Marketers of Tykerb, Nexavar, Sutent, and Sprycel need to address the fact that some MCOs appear to perceive Herceptin/Tykerb, Nexavar/Sutent, and Gleevec/Sprycel as interchangeable, "me too" agents.

"Evidence demonstrates that patients who have failed Herceptin in the metastatic setting should switch to Tykerb, patients who have failed Gleevec should switch to Sprycel, and, according to National Cancer Institute guidelines, patients who fail Sutent could benefit from Nexavar," said Mary Fletcher-Louis, analyst at Decision Resources. "To have only one from each of these couplets on formulary leaves important clinical scenarios uncovered."

Premium-Priced Targeted Agents in Oncology: Clinician and Payer Attitudes to Polypharmacy is based on a U.S. survey of 100 oncologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical and economic factors in the management of premium-priced targeted agents in oncology.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high-volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emerging technology companies receive significant funding
2. Genzyme acquistion of Bone Care approved, significant impact forecast
3. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
4. Manufacturing group says efforts led to big improvements
5. Part 6 Project Performance Get on the path to continuous improvement
6. Part 5 Project Performance Get on the path to continuous improvement
7. Part 4 Project Performance Get on the path to continuous improvement
8. Part 3 Project performance Get on the path to continuous improvement
9. Part 2 Project performance Get on the path to continuous improvement
10. Part 1 Project performance Get on the path to continuous improvement
11. Finding a Yardstick For Local Biotech Improvement and Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader ... to its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories ... and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 ... ... and NeuroTech NYC , the sensor and data driven conferences, will take place ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas P. ... in The Woodlands, Texas , now ... percent of treated fat cells in just 25-minutes, leaving ... to 90 percent of Americans report feeling bothered by ... fat reduction procedures are a growing industry. This innovative ...
(Date:5/3/2016)... Angeles, Calif (PRWEB) , ... May 03, 2016 ... ... of industry leading fertility clinics and IVF laboratories. A contingency of reproductive endocrinologists, ... to treat men and women experiencing infertility and to help them build families. ...
Breaking Biology Technology:
(Date:3/2/2016)... , March 2, 2016 ... announced the addition of the  "Global Biometrics ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... to grow at a CAGR of around ... ) has announced the addition of ...
(Date:3/1/2016)... 1, 2016 ... of the  "Global Biometric Access Control ... their offering. --> http://www.researchandmarkets.com/research/ghsgdt/global_biometric ... the  "Global Biometric Access Control Systems ... offering. --> Research and ...
(Date:3/1/2016)... and SAN FRANCISCO , March 1, ... Corp. and BitGo, Inc. extends biometric authentication to the ... private keys. Bitcoin transactions that ... per month in digital assets with over 10,000 transactions ... any startup. HYPR enables enterprises to keep encrypted biometric ...
Breaking Biology News(10 mins):